Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.
about
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and managementStructural biology of human cannabinoid receptor-2 helix 6 in membrane-mimetic environmentsPharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategiesFunctional Metabolomics Reveals Novel Active Products in the DHA MetabolomeLigand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation.The endocannabinoid system: a new pharmacological target for obesity treatment?Difference and Influence of Inactive and Active States of Cannabinoid Receptor Subtype CB2: From Conformation to Drug Discovery.Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modalityPhysical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptorsCentral mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in ratsMarijuana-based drugs: innovative therapeutics or designer drugs of abuse?The role of endocannabinoids in pain modulation.Beneficial metabolic effects of CB1R anti-sense oligonucleotide treatment in diet-induced obese AKR/J mice.Marijuana and body weight(4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229): a new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs.Changes in plasma levels of N-arachidonoyl ethanolamine and N-palmitoylethanolamine following bariatric surgery in morbidly obese females with impaired glucose homeostasis.Sex and cannabinoid CB1 genotype differentiate palatable food and cocaine self-administration behaviors in miceTherapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonistSolid-state NMR and molecular dynamics characterization of cannabinoid receptor-1 (CB1) helix 7 conformational plasticity in model membranesComprehensive profiling of the human circulating endocannabinoid metabolome: clinical sampling and sample storage parametersBlocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studiesThe endocannabinoid system: a new molecular target for the treatment of tobacco addiction.Endocannabinoid-mediated control of synaptic transmission.Dynamic conformational responses of a human cannabinoid receptor-1 helix domain to its membrane environment.Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis.Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.Anti-obesity drugs: past, present and future.The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects.The multiple functions of the endocannabinoid system: a focus on the regulation of food intakeBlockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel MonkeysIntrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats.Naphthalene and 2,3-dihydrobenzo[b][1,4]dioxine derivatives with extended side chains as new scaffolds of CB2-selective ligands
P2860
Q24649618-CDD66171-A11C-4336-9C5C-C4AD4FE18B0BQ27655311-07B5D8A5-AFBF-4E73-BABC-6639E802762FQ28241318-5E5AAACC-DA09-462B-9E2C-3747476A8E2FQ28266178-8587F311-A1D9-4FFC-8627-27A6E420D090Q30373403-BC01DF5C-C671-4825-81D8-C71FE3250967Q30377157-0C213C8D-2A31-41CD-9D8F-5BFD633AAD40Q33574533-8E7BFAB3-B592-401B-AE14-C55A001E6E75Q34018061-C54B2B28-8B7E-423D-A060-06F9D2E025FAQ34098252-EC10FFCC-9B60-467A-983D-020D984C99C1Q34168253-93B991B7-0699-4C54-887A-AEC175434502Q34173626-F0FB16A9-9DC5-478B-BC73-65C174966781Q34320270-2E0EFD80-6F09-4D6A-B643-41D0683A5840Q34369293-F067EB80-0225-44D4-93B1-7D87E6D3E4AEQ34377446-CDBE066D-76C1-4008-A855-9BF63C17462BQ34946743-490EF23D-1BF5-48D4-8CD9-386EEF66EACBQ35271208-79106945-DA6A-4A09-A478-5DD1CC63F085Q36057601-B280E227-EDE2-4CBA-A4B5-A3A21CE9E0ECQ36385052-B3F983BC-34CC-4D4D-91B8-520CA9E8F735Q37016808-75E006F0-AF1B-4C70-B63B-B2BB60CF7A55Q37070235-AC5135DB-B559-4E4C-BD6A-F0A74E9380C9Q37164812-874DBDF6-BEA5-4D32-AE2C-8B12669CF169Q37291517-E9649A79-0021-47E8-82F1-D4DFDC6F59F3Q37363621-3F11F8D9-AEB2-4DD2-9665-DC061F283BF5Q37421646-3CD6079D-B05C-47E5-9E42-6ED7B5B4C735Q37679402-7D613333-8390-44AD-951B-01987B183C0FQ37862977-1B52139E-DC7C-4DBE-97E4-3AF5764C8AECQ38036925-8E7D168E-46F3-4F57-A713-207D72FEB68EQ38072364-71F96580-ABDB-4BFE-A789-81856A8CD646Q39419099-DB686754-351E-496B-9808-C66A8960AFF3Q41873288-DF9673E5-B9BF-4D58-B266-61CD182BF539Q43194095-6DB9A07B-C80D-42E3-A0C1-6631E730E964Q52842340-C7183435-69AB-4525-9200-E6337322148EQ56784747-44753853-07C7-4ADC-8DC7-2265B7D0CE9F
P2860
Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Pharmacotherapeutic targeting ...... ty and the metabolic syndrome.
@ast
Pharmacotherapeutic targeting ...... ty and the metabolic syndrome.
@en
type
label
Pharmacotherapeutic targeting ...... ty and the metabolic syndrome.
@ast
Pharmacotherapeutic targeting ...... ty and the metabolic syndrome.
@en
prefLabel
Pharmacotherapeutic targeting ...... ty and the metabolic syndrome.
@ast
Pharmacotherapeutic targeting ...... ty and the metabolic syndrome.
@en
P2860
P921
P1476
Pharmacotherapeutic targeting ...... ty and the metabolic syndrome.
@en
P2093
David R Janero
V Kiran Vemuri
P2860
P304
P356
10.1016/J.PHYSBEH.2007.11.012
P407
P577
2007-11-21T00:00:00Z